Novo Nordisk announced on 11/8/2023 that their long-acting insulin, Levemir®, will be phased out from United States markers completely discontinuing by December 2024. It cited manufacturing constraints, reduced patient access and available alternatives. Novo Nordisk to discontinue Levemir insulin in U.S. market | Reuters
Reported timeline:
- Mid-January: expected supply disruptions of Levemir® FlexPen®
- April 1, 2024: Levemir® FlexPen® will be discontinued
- December 31: 2024, Levemir® vial will be discontinued
Posted in Drug Alerts/Recalls